

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 12 January 2024

FOI Ref No: 23281

Requested Information

1) How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Deucravacitinib
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab

2) How many patients were treated in the last 3 months by the Dermatology department for Psoriasis ONLY in the last three months with the following:

- Ciclosporin
- Methotrexate - any form and strength
- Methotrexate injections 15mg and above

Response

1) How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira 0
- Adalimumab Biosimilar 170
- Apremilast 16
- Bimekizumab 0
- Brodalumab 11
- Certolizumab 4
- Deucravacitinib 0
- Dimethyl fumarate 0
- Etanercept – Enbrel 1
- Etanercept Biosimilar 9
- Guselkumab 4
- Infliximab – Remicade 0
- Infliximab Biosimilar 2
- Ixekizumab 12
- Risankizumab 25
- Secukinumab 24
- Tildrakizumab 9
- Ustekinumab 39

2) How many patients were treated in the last 3 months by the Dermatology department for Psoriasis ONLY in the last three months with the following:

We do not record indication, so the below figures are for any medical condition

- Ciclosporin 22
- Methotrexate - any form and strength 90
- Methotrexate injections 15mg and above 2

Attachment(s)

None

Date Response sent: